Journal
ACS MEDICINAL CHEMISTRY LETTERS
Volume 2, Issue 9, Pages 708-713Publisher
AMER CHEMICAL SOC
DOI: 10.1021/ml200143c
Keywords
DHODH; malaria; P. falciparum; drug candidate
Categories
Funding
- SPARC from the Broad Institute, Medicines for Malaria Venture
- Humanitarian Assistance for Neglected Diseases Initiative at Genzyme Corporation
Ask authors/readers for more resources
Inhibition of dihydroorotate dehydrogenase (DHODH) for P. falciparum potentially represents a new treatment option for malaria, since DHODH catalyzes the rate-limiting step in the pyrimidine biosynthetic pathway and P. falciparum is unable to salvage pyrimidines and must rely on de novo biosynthesis for survival. We report herein the synthesis and structure-activity relationship of a series of 5-(2-methylbenzimidazol-1-yl)-N-alkylthiophene-2-carboxamides that are potent inhibitors against PfDHODH but do not inhibit the human enzyme. On the basis of efficacy observed in three mouse models of malaria, acceptable safety pharmacology risk assessment and safety toxicology profile in rodents, lack of potential drug-drug interactions, acceptable ADME/pharmacokinetic profile, and projected human dose, 5-(4-cyano-2-methyl-1H-benzo[d]imidazol-1-yl)-N-cyclopropylthiophene-2-carboxamide 2q was identified as a potential drug development candidate.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available